Treatment beyond progression: is it moving from belief to evidence? - Wikidata - wikimedia - TriplyDB

Treatment beyond progression: is it moving from belief to evidence?

Treatment beyond progression: is it moving from belief to evidence?

http://www.wikidata.org/entity/Q42995231

about

Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients Second-Line Treatment of Her2-Positive Metastatic Breast Cancer: Trastuzumab beyond Progression or Lapatinib? A Population Based Cohort Study.New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines.Trastuzumab beyond progression in retrospective analyses: an issue of equal opportunities.

P2860

Q33644305-B366621B-D86B-4752-A743-D120DBCF72DE Q35777143-F07ACB70-289B-49D8-8DCA-F087D4B83137 Q37620907-F8F30A67-4DFB-48E0-9CD2-B65079212EEF Q38215394-1144A4E1-8E2D-47F8-B11C-5EDA0CCED428 Q42995515-C1C08D37-95DC-4598-90D1-CC4F01D28405

P2860

Treatment beyond progression: is it moving from belief to evidence?

http://www.wikidata.org/entity/Q42995231

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Treatment beyond progression: is it moving from belief to evidence?

@en

Treatment beyond progression: is it moving from belief to evidence?

@nl

type

label

Treatment beyond progression: is it moving from belief to evidence?

@en

Treatment beyond progression: is it moving from belief to evidence?

@nl

prefLabel

Treatment beyond progression: is it moving from belief to evidence?

@en

Treatment beyond progression: is it moving from belief to evidence?

@nl

P1433

Q42995231-95BCAC98-9941-4F25-B53A-4A399079AA2D

P1476

Q42995231-9A1F33C0-7D67-4FDE-8E1C-AD8AD6577CC5

P2093

Q42995231-27D04D77-AD13-47A8-9FB8-130C388CE27E

Q42995231-3706C6BB-9703-4456-80B4-C8CD977B7D25

P2860

Q42995231-06E3CD49-632B-45D1-B310-4BB8857283B4

Q42995231-18F7531F-6FDA-4BC9-A83E-B0CF2BBAD243

Q42995231-3FF5E056-A1FD-413F-B42B-7013882ABA5D

Q42995231-6BCAE488-4753-487E-AA1C-0DCFB52E38DC

Q42995231-75A6BB76-6EC9-499C-9E8C-CEA721E205D1

Q42995231-814B4024-C9C9-4F6B-B7E3-E2AA49779FB8

Q42995231-852D6524-E327-4FF1-AF14-8B68C89C8186

Q42995231-B0A434BE-5FCC-4038-A726-36E4A2CC62E8

Q42995231-B5F3F366-BCFF-442D-8851-1C39477486CF

Q42995231-B80170C3-B266-42CE-AB09-19B7EF7798B5

P304

Q42995231-B944C22F-09C0-44B2-AB26-BEAE5F72696F

P31

Q42995231-5f957c49-8676-495c-bc41-9b1b75eca33f

Q42995231-FD344A23-DB71-44DC-BF65-D94F600FC935

P356

Q42995231-1787A9A9-182F-45D3-8FB3-B2C5A7D744C2

P433

Q42995231-3CFFFD85-4995-4326-9E4F-252F6289F208

P478

Q42995231-F2988EF0-0400-46D6-B71D-85BD14CCC4E2

P577

Q42995231-3B1B4739-226A-4EBC-B4BA-D0B5FADEE5B2

P5875

Q42995231-7A219567-6732-4756-810A-9F3EFDB8F51D

P698

Q42995231-1B4F7BFC-69E1-442B-BA0A-3E746D0FC58C

P932

Q42995231-CCD04C66-9348-4C8B-ACEC-7CD742E303C1

P356

THEONCOLOGIST.2010-0137

P1433

P1476

Treatment beyond progression: is it moving from belief to evidence?

@en

P2093

Karen Gelmon

http://www.w3.org/2001/XMLSchema#string

Rinat Yerushalmi

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study.

Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group.

Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study.

Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories.

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.

Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer.

Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression.

P304

796-798

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2010-0137

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2010-07-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45423838

http://www.w3.org/2001/XMLSchema#string

P698

20671106

http://www.w3.org/2001/XMLSchema#string

P932

3228025

http://www.w3.org/2001/XMLSchema#string